胺碘酮治疗快速型心律失常的临床效果
|
摘要
目的探究胺碘酮治疗快速型心律失常的临床效果。方法回顾性分析2016年4月至2017年7月于我院接受治疗的142例快速型心律失常患者的临床资料,依据治疗方法的不同将患者分为观察组和对照组,各71例。两组患者均进行基础治疗,在此基础上,观察组患者给予胺碘酮治疗,对照组给予利多卡因治疗。比较两组患者入院前及治疗后舒张压、收缩压及心率;观察两组患者的临床疗效与不良反应发生情况。结果入院前,两组患者舒张压、收缩压及心率比较,差异不具有统计学意义(P>0.05);治疗后,两组患者舒张压、收缩压及心率均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。观察组的治疗总有效率显著高于对照组,差异具有统计学意义(P<0.05)。观察组和对照组的不良反应总发生率比较,差异不具有统计学意义(P>0.05)。结论胺碘酮在快速型心率失常患者治疗中的应用效果良好,其可同时对患者的心率、血压进行有效控制,且不良反应发生率低,值得临床推广应用。
Objective To explore the clinical effect of amiodarone in the treatment of tachyarrhythmia. Methods The clinical data of 142 patients with tachyarrhythmia treated in our hospital from April 2016 to July 2017 were retrospectively analyzed. According to different treatment methods, the patients were divided into observation group and control group, with71 cases in each group. The patients of both groups were given basic treatment, on this basis, the observation group was given amiodarone treatment, the control group was given lidocaine treatment. The diastolic blood pressure, systolic blood pressure and heart rate before admission and after treatment were compared between the two groups; the clinical effects and adverse reactions of the two groups were observed. Results Before admission, there were no significant differences in diastolic blood pressure, systolic blood pressure and heart rate between the two groups(P>0.05); after treatment, the diastolic blood pressure,systolic blood pressure and heart rate of the two groups decreased, and those in the observation group were lower than the control group, with statistical significance(P <0.05). The total effective rate of treatment in the observation group was significantly higher than that of the control group(P<0.05). There was no significant difference in total incidence of adverse reactions between the observation group and the control group(P>0.05). Conclusion Amiodarone has a good effect in the treatment of patients with tachyarrhythmia. It can effectively control the heart rate and blood pressure of patients at the same time, and the incidence of adverse reactions is low. It is worthy of clinical popularization and application.
Objective To explore the clinical effect of amiodarone in the treatment of tachyarrhythmia. Methods The clinical data of 142 patients with tachyarrhythmia treated in our hospital from April 2016 to July 2017 were retrospectively analyzed. According to different treatment methods, the patients were divided into observation group and control group, with71 cases in each group. The patients of both groups were given basic treatment, on this basis, the observation group was given amiodarone treatment, the control group was given lidocaine treatment. The diastolic blood pressure, systolic blood pressure and heart rate before admission and after treatment were compared between the two groups; the clinical effects and adverse reactions of the two groups were observed. Results Before admission, there were no significant differences in diastolic blood pressure, systolic blood pressure and heart rate between the two groups(P>0.05); after treatment, the diastolic blood pressure,systolic blood pressure and heart rate of the two groups decreased, and those in the observation group were lower than the control group, with statistical significance(P <0.05). The total effective rate of treatment in the observation group was significantly higher than that of the control group(P<0.05). There was no significant difference in total incidence of adverse reactions between the observation group and the control group(P>0.05). Conclusion Amiodarone has a good effect in the treatment of patients with tachyarrhythmia. It can effectively control the heart rate and blood pressure of patients at the same time, and the incidence of adverse reactions is low. It is worthy of clinical popularization and application.
引文
[1]王小伟.急诊应用胺碘酮治疗快速型心律失常的疗效评价[J].中国医药导报,2010,7(10):107-108.
[2]吴建英.胺碘酮治疗急性心肌梗死合并室性心律失常临床疗效分析[J].中外医疗,2013,32(32):115-116.
[3]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心血管病预防指南[J].人人健康,2016,5(14):263-279.
[4]徐晓虹,杜珂,巩霞,等.急诊应用胺碘酮治疗快速型心律失常临床效果观察[J].中国继续医学教育,2015,28(16):118-119.
[5]郝嘉,游凯.心肌成纤维细胞的特性和调节[J].心血管病学进展,2011,32(3):405-408.
[6]李洁,刘乃丰,魏芹.罗格列酮对糖尿病大鼠心肌纤维化及核因子κB、结缔组织生长因子表达的影响[J].中国新药与临床杂志,2008,27(3):169-172.
[7]纪铭月.胺碘酮在冠心病快速室性心律失常中的应用及对心电变化的影响[J].医学综述,2015,21(22):4195-4196.
[8]陈娟.静脉滴注胺碘酮治疗高龄急性心肌梗死合并快速心律失常患者的临床疗效[J].实用临床医药杂志,2016,20(5):165-166.
[9]沈彩云,沈景云.胺碘酮治疗快速性心律失常68例临床分析[J].中外医疗,2012,10(14):12-13.
[10]赵丽萍.胺碘酮在急诊治疗快速型心律失常中的应用疗效观察[J].吉林医学,2014,35(6):1198.
[2]吴建英.胺碘酮治疗急性心肌梗死合并室性心律失常临床疗效分析[J].中外医疗,2013,32(32):115-116.
[3]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心血管病预防指南[J].人人健康,2016,5(14):263-279.
[4]徐晓虹,杜珂,巩霞,等.急诊应用胺碘酮治疗快速型心律失常临床效果观察[J].中国继续医学教育,2015,28(16):118-119.
[5]郝嘉,游凯.心肌成纤维细胞的特性和调节[J].心血管病学进展,2011,32(3):405-408.
[6]李洁,刘乃丰,魏芹.罗格列酮对糖尿病大鼠心肌纤维化及核因子κB、结缔组织生长因子表达的影响[J].中国新药与临床杂志,2008,27(3):169-172.
[7]纪铭月.胺碘酮在冠心病快速室性心律失常中的应用及对心电变化的影响[J].医学综述,2015,21(22):4195-4196.
[8]陈娟.静脉滴注胺碘酮治疗高龄急性心肌梗死合并快速心律失常患者的临床疗效[J].实用临床医药杂志,2016,20(5):165-166.
[9]沈彩云,沈景云.胺碘酮治疗快速性心律失常68例临床分析[J].中外医疗,2012,10(14):12-13.
[10]赵丽萍.胺碘酮在急诊治疗快速型心律失常中的应用疗效观察[J].吉林医学,2014,35(6):1198.